Logo image of BLRX

BIOLINERX LTD-SPONS ADR (BLRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BLRX - US09071M2052 - ADR

3.04 USD
+0.08 (+2.7%)
Last: 12/19/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, BLRX scores 1 out of 10 in our fundamental rating. BLRX was compared to 529 industry peers in the Biotechnology industry. Both the profitability and financial health of BLRX have multiple concerns. BLRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BLRX has reported negative net income.
BLRX had a negative operating cash flow in the past year.
BLRX had negative earnings in each of the past 5 years.
BLRX had a negative operating cash flow in each of the past 5 years.
BLRX Yearly Net Income VS EBIT VS OCF VS FCFBLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

BLRX has a better Return On Assets (-7.48%) than 84.88% of its industry peers.
With an excellent Return On Equity value of -15.24%, BLRX belongs to the best of the industry, outperforming 85.63% of the companies in the same industry.
Industry RankSector Rank
ROA -7.48%
ROE -15.24%
ROIC N/A
ROA(3y)-50.4%
ROA(5y)-49.58%
ROE(3y)-191.99%
ROE(5y)-150.4%
ROIC(3y)N/A
ROIC(5y)N/A
BLRX Yearly ROA, ROE, ROICBLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

BLRX's Gross Margin of 50.69% is fine compared to the rest of the industry. BLRX outperforms 75.80% of its industry peers.
The Profit Margin and Operating Margin are not available for BLRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLRX Yearly Profit, Operating, Gross MarginsBLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

BLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLRX has more shares outstanding than it did 1 year ago.
BLRX has more shares outstanding than it did 5 years ago.
BLRX has a worse debt/assets ratio than last year.
BLRX Yearly Shares OutstandingBLRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
BLRX Yearly Total Debt VS Total AssetsBLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -13.12, we must say that BLRX is in the distress zone and has some risk of bankruptcy.
BLRX has a Altman-Z score of -13.12. This is in the lower half of the industry: BLRX underperforms 77.88% of its industry peers.
BLRX has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.34, BLRX is not doing good in the industry: 70.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -13.12
ROIC/WACCN/A
WACC38.13%
BLRX Yearly LT Debt VS Equity VS FCFBLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 2.09 indicates that BLRX has no problem at all paying its short term obligations.
BLRX has a Current ratio of 2.09. This is in the lower half of the industry: BLRX underperforms 76.37% of its industry peers.
BLRX has a Quick Ratio of 1.93. This is a normal value and indicates that BLRX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.93, BLRX is not doing good in the industry: 76.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 1.93
BLRX Yearly Current Assets VS Current LiabilitesBLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

BLRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.78%, which is quite impressive.
BLRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -42.09%.
EPS 1Y (TTM)87.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.84%
Revenue 1Y (TTM)-42.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.36%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLRX Yearly Revenue VS EstimatesBLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 5M 10M 15M 20M 25M
BLRX Yearly EPS VS EstimatesBLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLRX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLRX Price Earnings VS Forward Price EarningsBLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLRX Per share dataBLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOLINERX LTD-SPONS ADR

NASDAQ:BLRX (12/19/2025, 8:00:02 PM)

3.04

+0.08 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24 2025-11-24
Earnings (Next)03-19 2026-03-19
Inst Owners0%
Inst Owner Change-58.17%
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap11.31M
Revenue(TTM)12.73M
Net Income(TTM)-2.98M
Analysts100
Price TargetN/A
Short Float %5%
Short Ratio6.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.89
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 1.24
EV/EBITDA N/A
EPS(TTM)-1.54
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.62
FCFYN/A
OCF(TTM)-3.62
OCFYN/A
SpS3.42
BVpS5.25
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.48%
ROE -15.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.69%
FCFM N/A
ROA(3y)-50.4%
ROA(5y)-49.58%
ROE(3y)-191.99%
ROE(5y)-150.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 1.93
Altman-Z -13.12
F-Score3
WACC38.13%
ROIC/WACCN/A
Cap/Depr(3y)23.7%
Cap/Depr(5y)16.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.84%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-91.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y62.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y60.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.49%
OCF growth 3YN/A
OCF growth 5YN/A

BIOLINERX LTD-SPONS ADR / BLRX FAQ

Can you provide the ChartMill fundamental rating for BIOLINERX LTD-SPONS ADR?

ChartMill assigns a fundamental rating of 1 / 10 to BLRX.


What is the valuation status for BLRX stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOLINERX LTD-SPONS ADR (BLRX). This can be considered as Overvalued.


What is the profitability of BLRX stock?

BIOLINERX LTD-SPONS ADR (BLRX) has a profitability rating of 2 / 10.


Can you provide the financial health for BLRX stock?

The financial health rating of BIOLINERX LTD-SPONS ADR (BLRX) is 2 / 10.